WO2014064534A3 - Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation - Google Patents

Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation Download PDF

Info

Publication number
WO2014064534A3
WO2014064534A3 PCT/IB2013/003034 IB2013003034W WO2014064534A3 WO 2014064534 A3 WO2014064534 A3 WO 2014064534A3 IB 2013003034 W IB2013003034 W IB 2013003034W WO 2014064534 A3 WO2014064534 A3 WO 2014064534A3
Authority
WO
WIPO (PCT)
Prior art keywords
needle
array
apertures
deliver
center
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/003034
Other languages
English (en)
Other versions
WO2014064534A2 (fr
Inventor
Gustaf AHLEN
Lars Frelin
Matti Sallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chrontech Pharma AB
Original Assignee
Chrontech Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrontech Pharma AB filed Critical Chrontech Pharma AB
Publication of WO2014064534A2 publication Critical patent/WO2014064534A2/fr
Publication of WO2014064534A3 publication Critical patent/WO2014064534A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
    • A61M5/3291—Shafts with additional lateral openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
    • A61M5/3298—Needles arranged in parallel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne plusieurs ensembles aiguille et dispositifs d'administration intracellulaire, qui sont utilisés pour l'administration de matière prophylactique et/ou thérapeutique (c'est-à-dire des agents administrés) dans un tissu d'un sujet. De préférence, les ensembles aiguille et/ou les dispositifs d'administration intracellulaire comprennent des aiguilles et/ou des électrodes d'aiguille, qui sont disposées en un réseau (par exemple, un réseau du type Y ayant trois aiguilles externes et une aiguille centrale), chaque aiguille dans le réseau ayant une extrémité fermée et une pluralité d'ouvertures le long de chaque corps d'aiguille, et les ouvertures sur les corps d'aiguille des aiguilles externes du réseau étant positionnées pour administrer l'agent administré vers les ouvertures de l'aiguille centrale et/ou d'une aiguille adjacente, mais pas à l'extérieur de la zone active définie par la zone dans le réseau d'aiguilles, et les ouvertures sur le corps d'aiguille de l'aiguille centrale étant positionnées pour administrer l'agent administré vers les aiguilles externes. Les dispositifs peuvent être utilisés pour administrer des compositions immunogènes, telles que celles qui empêchent une réponse immunitaire au virus de l'hépatite C chez des individus naïfs ou infectés par le VHC de façon chronique.
PCT/IB2013/003034 2012-10-05 2013-10-04 Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation Ceased WO2014064534A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261710634P 2012-10-05 2012-10-05
US61/710,634 2012-10-05
US201361881391P 2013-09-23 2013-09-23
US61/881,391 2013-09-23

Publications (2)

Publication Number Publication Date
WO2014064534A2 WO2014064534A2 (fr) 2014-05-01
WO2014064534A3 true WO2014064534A3 (fr) 2014-11-06

Family

ID=50156793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003034 Ceased WO2014064534A2 (fr) 2012-10-05 2013-10-04 Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2014064534A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP2017000667A (ja) * 2015-06-16 2017-01-05 国立大学法人三重大学 無針注射器及びそれを用いた注射対象領域へのｄｎａ導入方法
JP7737718B2 (ja) * 2019-07-22 2025-09-11 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー マイクロチャネルを有するニードルのための技術
KR20220160042A (ko) 2020-03-27 2022-12-05 스벤스카 박신파브리셴 프로둑숀 아베 코로나바이러스의 치료 및 예방을 위한 조성물 및 방법
JP2023523857A (ja) 2020-05-04 2023-06-07 ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー 細胞の透過化およびトランスフェクションを強化するために吸引を使用するシステムおよび方法
CN115960244B (zh) * 2021-09-14 2026-02-17 上海鸣大生物科技有限公司 重组α-1,3-半乳糖基转移酶及其制备方法和应用
WO2023056284A1 (fr) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions et méthodes de traitement et de prévention d'infections à coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206919A1 (en) * 2000-08-17 2003-11-06 Matti Sallberg Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2011073796A2 (fr) * 2009-12-16 2011-06-23 Chrontech Pharma Ab Aiguille et dispositif d'injection

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5240855A (en) 1989-05-12 1993-08-31 Pioneer Hi-Bred International, Inc. Particle gun
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
SE9401460D0 (sv) 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6040137A (en) 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6019747A (en) 1997-10-21 2000-02-01 I-Flow Corporation Spring-actuated infusion syringe
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US6897068B2 (en) 1999-02-26 2005-05-24 Mirus Bio Corporation Polynucleotide complex delivery
US7015040B2 (en) 1999-02-26 2006-03-21 Mirus Bio Corporation Intravascular delivery of nucleic acid
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US7214369B2 (en) 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
AU3958101A (en) 2000-03-15 2001-09-24 Univ Pohang Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
CN1437481A (zh) 2000-06-22 2003-08-20 美国氰胺公司 作为佐剂组合的qs－21和il－12
US6440096B1 (en) 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6527216B2 (en) 2001-05-08 2003-03-04 Magnatech International Llp Electronic length control wire pay-off system and method
US7589059B2 (en) 2002-07-26 2009-09-15 Roche Madison Inc. Delivery of molecules and complexes to mammalian cells in vivo
WO2004032865A2 (fr) 2002-10-09 2004-04-22 Central Iowa Health System Vaccination anti-tumeur utilisant des cellules tumorales allogenes exprimant alpha (1,3)-galactosyltransferase
AU2003302152A1 (en) 2002-11-26 2004-06-18 Tripep Ab Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
KR20050099536A (ko) 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CA2534060C (fr) 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation
KR20080036598A (ko) 2005-08-01 2008-04-28 머크 앤드 캄파니 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드
WO2009130588A2 (fr) 2008-04-22 2009-10-29 Tripep Ab Plateforme immunogène
WO2010086743A2 (fr) 2009-02-02 2010-08-05 Chrontech Pharma Ab Compositions et procédés qui améliorent une réponse immunitaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206919A1 (en) * 2000-08-17 2003-11-06 Matti Sallberg Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2011073796A2 (fr) * 2009-12-16 2011-06-23 Chrontech Pharma Ab Aiguille et dispositif d'injection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRELIN L ET AL: "Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 10, 1 January 2003 (2003-01-01), pages 686 - 699, XP002285892, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3301933 *
GARCIA-NAVARRO R ET AL: "Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12", JOURNAL OF VIROLOGY, vol. 75, no. 19, October 2001 (2001-10-01), pages 9068 - 9076, XP002723966, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector

Also Published As

Publication number Publication date
WO2014064534A2 (fr) 2014-05-01

Similar Documents

Publication Publication Date Title
WO2012172424A9 (fr) Aiguille et dispositif d'injection
WO2015106269A3 (fr) Formulations d'insuline à action rapide et systèmes d'administration pharmaceutique
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
GT201400053A (es) Inhibidores de aplicación viral
CA2875824C (fr) Methodes de traitement du cancer du pancreas a l'aide de polytherapies comportant l'irinotecan en liposome
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
WO2015038818A3 (fr) Formulations de protéines liquides contenant des agents abaissant la viscosité
WO2015095624A3 (fr) Système et procédé de mélange et de libération d'un médicament
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
BR112015018904A2 (pt) limpador de desinfecção de orifício de acesso e conector sem agulha e cobertura de proteção antimicrobiana
WO2012164390A3 (fr) Auto-injecteur
HK1198869A1 (en) Combination treatments for hepatitis c
HK1252759A1 (zh) 肽寡核苷酸缀合物
EP2471926A3 (fr) Oligodésoxynucléotides immunostimulateurs
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
IN2014KN02583A (fr)
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
WO2013036309A3 (fr) Formulation à libération prolongée pour administration de protéines à l'œil, et leurs procédés de préparation
CA2915027A1 (fr) Compositions et procedes d'administration de vaccins contre le virus de la dengue
WO2016191458A3 (fr) Compositions pharmaceutiques ayant un effet sur l'état d'oxydoréduction mitochondriale et méthodes de traitement associées
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
EP3248639A4 (fr) Embout pour collecte de liquide à usage médical, buse de collecte de liquide, et set d'injecteur
WO2010019717A3 (fr) Thérapie de combinaison d'inhibiteurs de fusion/entrée du vih ciblant gp41

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13831860

Country of ref document: EP

Kind code of ref document: A2